10.1002/ejoc.201800188
European Journal of Organic Chemistry
FULL PAPER
65.3 (C-2), 115.8 (C-Ar ), 116.1 (C-Ar ), 119.8 (C-Ar), 125.1 (C-5, C-6, C-
7 or C-8), 127.4 (C-5 or C-8), 128.8 (C-6 or C-7), 130.8 (C-4a/b or C-Ar),
135.9 (C-4a/b or C-Ar), 136.3 (C-5, C-6, C-7 or C-8), 145.4 (C-Ar), 145.6
(C-Ar), 153.1 (C-4a/b or C-Ar), 171.5 (C-1’), 200.7 (C-1). IR ṽ 3448, 3261,
2984, 1713, 1686, 1604, 1590, 1517, 1469, 1441, 1365, 1328, 1264, 1214,
1190, 1158, 1139, 1118, 1083, 1050, 1027, 1013, 957, 921, 881, 863, 845,
812, 788, 766, 742, 692, 678, 659 cm-1. HRMS: m/z = 313.1073 [M+H]+,
calculated for C18H17O5+: 313.1071.
Salts for the different buffer systems were purchased from VWR
Chemicals, AppliChem Panreac ITW Companies and Carl ROTH®.
Trypsin from bovine pancreas as well as trypsin inhibitor were purchased
from Sigma Aldrich. Donor organism for the used plasmid, containing the
desired tyrosinase, was Aspergillus oryzae. The accession number of the
tyrosinase gene is BD165761, DNA Data Bank of Japan, Mishima-shi. No
synthetic gene was used. For further specific details, see ref. 14. Acceptor
organism is E. coli BL21 (DE3). The initial vector was a pET-30(+) vector
from Novagen. Complete description of the final GVO is: E.coli
c]
BL21/pETHmelB.[14a,
Expression of the tyrosinase in E. coli was
3-Acetyl-3-(3,4-dihydroxyphenyl)chroman-2-one (8h) was obtained as
colourless solid, 77% yield (34 mg, 115 µmol). Rf (70/30 PE/EtOAc): 0.12.
Mp: 242-243 °C (turned black from 220 °C on). 1H-NMR (600 MHz,
acetone-d6) [ppm] δ 2.03 (s, 3 H, 2‘-H), 3.60 (d, J = 16.3 Hz, 1 H, 3-Ha),
3.75 (d, J = 16.3 Hz, 1 H, 3-Hb), 6.68 (dd, J = 8.3, 2.4 Hz, 1 H, 14-H), 6.79
(d, J = 2.4 Hz, 1 H, 10-H), 6.82 (d, J = 8.3 Hz, 1 H, 13-H), 6.98 (d, J =
8.1 Hz, 1 H, 8-H), 7.08 (dd, J = 7.5 Hz, 1 H, 6-H), 7.24 (dd, J = 7.7 Hz, 1
H, 7-H), 7.33 (d, J = 7.6 Hz, 1H, 5-H), 8.00 (bs, OH), 8.13 (bs, OH). 13C-
NMR (151 MHz, aceton-d6) [ppm] δ 27.0 (C-2’), 32.3 (C-3), 63.6 (C-2),
115.6 (C-10),116.5 (C-13), 116.6 (C-8), 119.8 (C-14), 123.1 (C-4a or C-4b),
125.4 (C-6), 126.5 (C-9), 129.2 (C-7), 129.4 (C-5), 146.2 (C-11 or C-12),
146.3 (C-12 or C-11),152.1 (C-4a or C-4b), 168.0 (C-1’ or C-1), 203.7 (C-1
or C-1’). IR ṽ 3462, 3211, 1762, 1683, 1607, 1542, 1533, 1488, 1457, 1437,
1360, 1339, 1284, 1256, 1234, 1299, 1182, 1144, 1108, 1084, 1030, 979,
947, 916, 869, 834, 809, 795, 774, 761, 680 cm-1. HRMS m/z = 299.0915
[M+H]+, calculated for C17H15O5+: 299.0914; 321.0735 [M+Na], calculated
for C17H14O5Na: 321.0739.
performed in 1 L Fernbach flasks that were tempered and shaken in a New
Brunswick™ Innova® 42 shaker. Harvesting of the cells by centrifugation
was performed via the RC5B centrifuge from Thermo Scientific. Cell
disruption was performed via a Sonoplus or Sonoplus RC6 plus from
Bandelin electronic GmbH & Co.KG, Berlin. pH values of the different
buffer systems were adjusted via the Mikroprozessor-pH-Meter from Knick.
Transformation of E. coli BL21 with the pETH/melB plasmid was
performed by putting 3 µL of the plasmid (negative control with 3 µL of
sterilised water) onto competent cells keeping them for 30 min on ice. Heat
shock occurred for 90 sec at 42 °C. Afterwards 1 mL of LB medium was
added to the cells and incubated for 1 h at 37 °C. After centrifugation, the
supernatant was discarded and the pellet was re-suspended with the
holdover of the supernatant and distributed onto kanamycin agar plates,
which were incubated over night at 37 °C.
Preparatory cultures were prepared by picking one single E. coli
BL21/pETHmelB colony and transferring it into 5 mL LB medium with 5 µL
kanamycin (KAN). Incubation continued over night at 37 °C.
tert-Butyl
3-(3,4-dihydroxyphenyl)-2-oxo-3-phenylindoline-1-
carboxylate (8i) was obtained as slightly yellow solid, 53% yield (32 mg,
77 µmol). Rf (70/30 PE/EtOAc): 0.28. Mp: 87-88 °C. 1H-NMR (600 MHz,
acetone-d6) [ppm] δ 1.61 [s, 9 H, C(CH3)3], 5.50 (bs, OH), 5.75 (bs, OH),
6,55 (dd, J = 8.3, 2.2 Hz, 1 H, 14-H), 6.69 (d, J = 8.4 Hz, 1 H, 13-H), 6.76
(d, J = 2.2 Hz, 1 H, 10-H), 7.13-7.19 (m, 4 H, Ar-H), 7.21-7.32 (m, 4 H, Ar-
H), 7.87 (d, J = 8.2 Hz, 1 H, Ar-H). 13C-NMR (151 MHz, aceton-d6) [ppm]
δ 28.2 [C(CH3)3], 62.5 (C-3), 85.1 [C(CH3)3], 115.2 (C-13), 115.4 (C-Ar),
116.2 (C-10), 121.5 (C-14), 124.9 (C-Ar), 126.3 (C-Ar), 127.6 (C-Ar), 128.6
(2 C-Ar), 128.6 (2 C-Ar), 132.1 (C-Ar), 133.8 (C-Ar), 138.9 (C-Ar), 141.9
(C-Ar), 143.6 (C-Ar), 149.4 (C-2 or C-1‘), 177.0 (C-1‘ or C-2). IR ṽ 3393,
2980, 2930, 1781, 1733, 1603, 1517, 1495, 1478, 1464, 1434, 1395, 1370,
1341, 1309, 1284, 1251, 1143, 1115, 1092, 1034, 1001, 947, 909, 856,
837, 813, 753, 729, 696 cm-1. HRMS: m/z = 418.1649 [M+H]+, calculated
for C25H24NO5+: 418.1649; 440.1468 [M+Na], calculated for C25H23NO5Na:
440.1468.
Expression was performed in 1 L Fernbach flasks. One preparatory
culture was added to 1 L TB media [Terrific-Broth media from Carl
ROTH®; containing casein 12 g/L, yeast extract 24 g/L, K2HPO4 12.54 g/L
and KH2PO4 2.31 g/L, pH ~7.2; 1 mL KAN (50 mg/mL) and 1 M (1.2 mL)
CuSO4]. The expression started at 29 °C for 1 h, followed by 4 h at 36 °C
and again 1 h at 29 °C before induction with IPTG (100 µL, 10 mg/mL).
The culture was further shaken (120 rpm) over night at 21 °C. The cells
were harvested by centrifugation at 4 °C, 12.000 rpm (7084 rcf) for 20 min.
Afterwards the pellets were suspended with 0.85% NaCl solution and
centrifuged a second time before they were stored until further use at
-20 °C.
Purification of the enzyme occurred via a peristaltic pump P-1 from
Pharmacia and a Ni-NTA column. Following buffer systems were used for
protein purification [binding buffer: 0.3 M NaCl, 10 mM imidazole, 10%
glycerol; 20 mM Bis-Tris, pH 7.2; elution buffer I: 0.3 M NaCl, 0.1 M
imidazole, 0.5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP),
20 mM Bis-Tris, pH 7.2; elution buffer II: 0.3 M NaCl, 0.5 M imidazole,
0.5 mM TCEP, 20 mM Bis-Tris, pH 7.2]. 5 g of the cell pellet were
suspended ad 20 mL of the binding buffer and disrupted with the sonotrode
for three times 5 min on ice. The Ni-NTA column was washed with binding
buffer (10 mL) before the crude enzyme solution was put on it in flow for
30 min. Afterwards the column was washed again with 5-10 mL of the
binding buffer to elute unbound enzyme. In two steps (15 mL each) the
enzyme was eluted from the column using elution buffer I+II. Purification
of the Ni-NTA occurred with a 2 M imidazole solution, followed by washing
it with dH2O and stored in 20% EtOH.
Methyl
1-(4,5-dihydroxy-2-methoxyphenyl)-2-oxocyclopentane-1-
carboxylate (m-8n) was obtained as slightly yellow oil, 55% yield (23 mg,
82 µmol). Rf (70/30 PE/EtOAc): 0.07. 1H-NMR (600 MHz, CDCl3) [ppm] δ
1.84-1.91 (m, 1 H, 3-H or 4-H or 5-H), 1.95-2.02 (m, 1 H, 3-H or 4-H or 5-
H), 2.27 (m, 1 H, 3-H or 4-H or 5-H), 2.43-2.50 (m, 2 H, 3-H or 4-H or 5-H),
2.88 (mc, 1 H, 3-H or 4-H or 5-H), 3.67 (s, 3 H, 2‘-H or 7-H), 3.74 (s, 3 H,
7-H or 2‘-H ), 6.44 (s, 1 H, 8-H or 11-H), 6.49 (s, 1 H, 11-H or 8-H). 13C-
NMR (151 MHz, CDCl3) [ppm] δ 19.9 (C-3 or C-4 or C-5), 35.6 (C-3 or C-
4 or C-5), 38.7 (C-3 or C-4 or C-5), 53.1 (C-2‘ or C-7‘), 56.1 (C-2‘ or C-7‘),
64.4 (C-1), 101.3 (C-8 or C-11), 115.6 (C11 or C-8), 119.8 (C-6, C-7, C-9
or C-10), 136.4 (C-6, C-7, C-9 or C-10), 144.7 (C-6, C-7, C-9 or C-10),
151.4 (C-6, C-7, C-9 or C-10), 171.3 (C-2 or C-1‘), 215.1 (C-1‘ or C-2). IR
ṽ 3398, 2955, 1719, 1614, 1574, 1515, 1456, 1429, 1402, 1352, 1306,
1231, 1194, 1171, 1104, 1077, 1036, 1014, 986, 937, 912, 866, 832, 728,
647, 609, 563, 519. HRMS: m/z = 279.0863 [M-H]+, calculated for
For concentration of the protein solutions, Vivaspin 20 (10 kDa MWCO)
or Vivacell 250 from Sartorius Stedim were used. For buffer changes, PD-
10 columns from GE-Healthcare were used (Tris-HCl buffer: 10 mM Tris-
HCl, 10 mM NaCl, 10% glycerol, pH 6). Therefore, the PD-10 columns
were loaded each with 2.5 mL enzyme solution and eluted with 3.5 mL of
the Tris-HCl buffer.
C14H15O6 : 279.0874; 281.1020 [M+H]+, calculated for C14H17O6
281.1020.
:
-
+
Methods in Biology
This article is protected by copyright. All rights reserved.